Empagliflozin for heart failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 13 registered trials.

Also followed for narrower conditions: Heart Failure, Diastolic

Why this status

  1. 20 Feb 2017: Trial registered, NCT03057951
  2. 2 Mar 2017: Trial started, NCT03057951
  3. 28 Feb 2018: Trial registered, NCT03448406
  4. 20 Mar 2018: Trial started, NCT03448406
  5. 8 Nov 2019: Trial registered, NCT04157751
  6. 18 May 2020: Trial started, NCT04157751
  7. 31 Oct 2022: Trial registered, NCT05600387
  8. 5 Nov 2022: Trial started, NCT05600387
  9. 17 Mar 2023: Trial started, NCT06683053
  10. 15 Feb 2024: Trial registered, NCT06260059
  11. 17 Sep 2024: Trial started, NCT06260059
  12. 12 Nov 2024: Trial registered, NCT06683053

The trials

NCT03057951: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

State
Completed
Phase
Phase 3
People
5,988 taking part
Started
2 Mar 2017
Primary completion
26 Apr 2021
Arms
10 mg Empagliflozin
Results
Posted on the registry
Papers
doi:10.1001/jamacardio.2022.2924, doi:10.1001/jamacardio.2023.1090, doi:10.1002/14651858.cd013650.pub2, doi:10.1002/14651858.cd015588.pub2, doi:10.1002/ejhf.3101, doi:10.1002/ejhf.3166, doi:10.1002/jcsm.13393, doi:10.1016/j.jacc.2022.01.029, doi:10.1016/j.jchf.2022.05.004, doi:10.1016/j.jchf.2024.10.021, doi:10.1016/j.jchf.2025.102889, doi:10.1056/nejmoa2107038, doi:10.1093/eurheartj/ehac306, doi:10.1093/eurheartj/ehac495, doi:10.1093/eurheartj/ehac693, doi:10.1111/dom.13678, doi:10.1111/dom.15572, doi:10.1161/circulationaha.121.057812, doi:10.1161/circulationaha.121.058929, doi:10.1161/circulationaha.122.059755, doi:10.1161/circulationaha.122.059785, doi:10.1161/circulationaha.123.065748, doi:10.2217/fca-2023-0091
  1. 20 Feb 2017: Trial registered
  2. 2 Mar 2017: Trial started
  3. 26 Apr 2021: Trial completed
  4. 6 Jun 2022: Trial results posted

NCT03448406: This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

State
Completed
Phase
Phase 3
People
315 taking part
Started
20 Mar 2018
Primary completion
4 Oct 2019
Arms
Empagliflozin
Results
Posted on the registry
Papers
doi:10.1002/ejhf.1486, doi:10.1111/dom.13678, doi:10.1161/circulationaha.121.054669
  1. 28 Feb 2018: Trial registered
  2. 20 Mar 2018: Trial started
  3. 9 Oct 2019: Trial completed
  4. 8 Dec 2020: Trial results posted

NCT04157751: A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

State
Completed
Phase
Phase 3
People
530 taking part
Started
18 May 2020
Primary completion
28 May 2021
Arms
Empagliflozin
Results
Posted on the registry
Papers
doi:10.1002/ejhf.2982, doi:10.1016/j.jchf.2026.102999, doi:10.1038/s41591-021-01659-1, doi:10.1161/circulationaha.122.059725, doi:10.1681/asn.0000000766
  1. 8 Nov 2019: Trial registered
  2. 18 May 2020: Trial started
  3. 2 Jun 2021: Trial completed
  4. 6 Jun 2022: Trial results posted

NCT05553938: Effects of Acute and Chronic Empagliflozin Heart Failure

State
Under way
Phase
Phase 1
People
60 taking part
Started
4 Aug 2023
Primary completion
8 May 2026
Arms
Empagliflozin
Results
None posted
  1. 26 Sep 2022: Trial registered
  2. 4 Aug 2023: Trial started

NCT05580510: " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

State
State not given
Phase
Phase 2 and Phase 3
People
160 planned
Started
6 Feb 2023
Primary completion
28 Jul 2023
Arms
Conventional treatment plus Empagliflozin and Sacubitril/valsartan, Conventional treatment plus Empagliflozin
Results
None posted
Papers
doi:10.1002/ejhf.1342, doi:10.1056/nejmoa2022190, doi:10.1093/eurheartj/ehaa1012, doi:10.1161/circulationaha.120.052186, doi:10.1161/circulationaha.121.053659
  1. 14 Oct 2022: Trial registered

NCT05584319: EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction

State
State not given
Phase
Phase 4
People
100 planned
Started
15 Dec 2022
Primary completion
Oct 2024
Arms
Empagliflozin group
Results
None posted
  1. 18 Oct 2022: Trial registered

NCT05600387: Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

State
State not given
Phase
Phase 4
People
100 planned
Started
5 Nov 2022
Primary completion
Oct 2024
Arms
Empagliflozin group
Results
None posted
  1. 31 Oct 2022: Trial registered
  2. 5 Nov 2022: Trial started

NCT05967156: Empagliflozin in Heart Failure Dialysis Patients

State
Completed
Phase
No phase
People
30 taking part
Started
1 Jun 2023
Primary completion
1 Jun 2025
Arms
Empagliflozin
Results
None posted
  1. 1 Jun 2023: Trial started
  2. 1 Aug 2023: Trial registered
  3. 3 Jun 2025: Trial completed

NCT06260059: Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

State
Under way
Phase
Phase 4
People
40 planned
Started
17 Sep 2024
Primary completion
31 Dec 2026
Arms
Empagliflozin 10 MG
Results
None posted
  1. 15 Feb 2024: Trial registered
  2. 17 Sep 2024: Trial started

NCT06570473: Feasibility Trial for a Right Ventricular Failure Platform Trial

State
Under way
Phase
Phase 2
People
30 planned
Started
15 Jul 2025
Primary completion
31 Mar 2027
Arms
Empagliflozin
Results
None posted
  1. 26 Aug 2024: Trial registered
  2. 15 Jul 2025: Trial started

NCT06683053: Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

State
Under way
Phase
Phase 3
People
90 taking part
Started
17 Mar 2023
Primary completion
29 Apr 2024
Arms
Empagliflozin 10 mg, Empagliflozin 25 mg
Results
None posted
  1. 17 Mar 2023: Trial started
  2. 12 Nov 2024: Trial registered

NCT06915870: Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

State
Completed
Phase
No phase
People
108 taking part
Started
12 Jul 2024
Primary completion
13 Jan 2025
Arms
In group B, patients were prescribed Empagliflozin 10 mg daily for 12 weeks
Results
None posted
  1. 12 Jul 2024: Trial started
  2. 13 Jan 2025: Trial completed
  3. 8 Apr 2025: Trial registered

NCT07556094: Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.

State
Completed
Phase
No phase
People
70 taking part
Started
5 Jun 2023
Primary completion
9 May 2025
Arms
Empagliflozin + Background Heart Failure Therapy
Results
None posted
  1. 5 Jun 2023: Trial started
  2. 9 May 2025: Trial completed
  3. 29 Apr 2026: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.